S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma
First International Summit on Interventional PharmacoeconomicsAdvertisement
Related Videos
Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib
Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.
Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States
Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.
Advertisement
Advertisement
Nov
Today In Oncology28
Advertisement
© 2022 HSP News Service, L.L.C.
